Stock listing

Shin Nippon Biomedical Laboratories, Ltd.

Selected listing: YB3 · DUS · EUR · DE

Shin Nippon Biomedical Laboratories, Ltd. (Dusseldorf:YB3), Commercial Services. Latest release Aug 5, 2026: Consolidated Financial Results for the Three…

YB3:DUSEURDEUpdated October 3, 2026

Ticker: Dusseldorf:YB3
Asset type: Stock
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
Exchange: Dusseldorf
Currency: EUR

Latest news from Shin Nippon Biomedical Laboratories, Ltd.

Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)

August 4, 2026

Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache

November 5, 2025

Shin Nippon Biomedical Laboratories : ガバナンスに関するデータ

August 26, 2025

Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting

June 19, 2025

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

April 29, 2025

All Shin Nippon Biomedical Laboratories, Ltd. news →

Research Shin Nippon Biomedical Laboratories, Ltd.

Shin Nippon Biomedical Laboratories, Ltd. company profile

View the public company page for Shin Nippon Biomedical Laboratories, Ltd. on 6ix.

Shin Nippon Biomedical Laboratories, Ltd. news

Read company news and market updates connected to Shin Nippon Biomedical Laboratories, Ltd..

Shin Nippon Biomedical Laboratories, Ltd. investor events

Find investor webinars, events, and replay context for Shin Nippon Biomedical Laboratories, Ltd..